Transarterial chemoembolization: Modalities, indication, and patient selection

Journal of Hepatology

Volumn 62, Issue 5, 2015, Pages 1187-1195

  Sieghart, Wolfgang ^a   Hucke, Florian ^a   Peck Radosavljevic, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

HCC; Hepatocellular carcinoma; Intermediate stage; mRECIST; Overall survival; Patient selection; Response; TACE

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMOEMBOLIZATION; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETREATMENT; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADVERSE EFFECTS; CARCINOMA, HEPATOCELLULAR; LIVER; LIVER NEOPLASMS; PATHOLOGY; PROCEDURES; PROGNOSIS; RADIOGRAPHY; RISK ASSESSMENT;

CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; HUMANS; LIVER; LIVER NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SELECTION; PROGNOSIS; RISK ADJUSTMENT;

EID: 84927789057     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.02.010     Document Type: Review

References (79)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. A. Forner, M.E. Reig, C.R. de Lope, and J. Bruix Current strategy for staging and treatment: the BCLC update and future prospects Semin Liver Dis 30 2010 61 74
3. J.M. Llovet, C. Bru, and J. Bruix Prognosis of hepatocellular carcinoma: the BCLC staging classification Semin Liver Dis 19 1999 329 338
4. European Association For The Study Of The Liver European Organisation For Research Treatment Of Cancer EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma J Hepatol 56 2012 908 943
5. J. Bruix, M. Sherman American Association for the Study of Liver Disease Management of hepatocellular carcinoma: an update Hepatology 53 2011 1020 1022
6. F. Hucke, W. Sieghart, M. Schoniger-Hekele, M. Peck-Radosavljevic, and C. Muller Clinical characteristics of patients with hepatocellular carcinoma in Austria - Is there a need for a structured screening program? Wien Klin Wochenschr 123 2011 542 551
7. J.M. Llovet, M.I. Real, X. Montana, R. Planas, S. Coll, and J. Aponte Arterial embolisation or chemoembolisation vs. symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Lancet 359 2002 1734 1739
8. J.M. Llovet, and J. Bruix Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival Hepatology 37 2003 429 442
9. J. Bruix, J.M. Llovet, A. Castells, X. Montana, C. Bru, and M.C. Ayuso Transarterial embolization vs. symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution Hepatology 27 1998 1578 1583
10. Hepatocellulaire GdEedTdC A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire N Engl J Med 332 1995 1256 1261
11. D.Y. Lin, Y.F. Liaw, T.Y. Lee, and C.M. Lai Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma - A randomized controlled trial Gastroenterology 94 1988 453 456
12. C.M. Lo, H. Ngan, W.K. Tso, C.L. Liu, C.M. Lam, and R.T. Poon Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma Hepatology 35 2002 1164 1171
13. G. Pelletier, M. Ducreux, F. Gay, M. Luboinski, H. Hagege, and T. Dao Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC J Hepatol 29 1998 129 134
14. G. Pelletier, A. Roche, O. Ink, M.L. Anciaux, S. Derhy, and P. Rougier A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma J Hepatol 11 1990 181 184
15. C. Camma, F. Schepis, A. Orlando, M. Albanese, L. Shahied, and F. Trevisani Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials Radiology 224 2002 47 54
16. L. Marelli, R. Stigliano, C. Triantos, M. Senzolo, E. Cholongitas, and N. Davies Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies Cardiovasc Intervent Radiol 30 2007 6 25
17. K. Malagari, M. Pomoni, A. Kelekis, A. Pomoni, S. Dourakis, and T. Spyridopoulos Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma Cardiovasc Intervent Radiol 33 2010 541 551
18. T. Meyer, A. Kirkwood, M. Roughton, S. Beare, E. Tsochatzis, and D. Yu A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs. embolisation alone for hepatocellular carcinoma Br J Cancer 108 2013 1252 1259
19. C. Verslype, O. Rosmorduc, P. Rougier Group EGW Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 23 2012 vii41 vii48
20. R.S. Oliveri, J. Wetterslev, and C. Gluud Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma Cochrane Database Syst Rev 2011 CD004787
21. A. Forner, J.M. Llovet, and J. Bruix Chemoembolization for intermediate HCC: is there proof of survival benefit? J Hepatol 56 2012 984 986
22. S.C. Rose, S.G. Kikolski, R.G. Gish, Y. Kono, R. Loomba, and A.W. Hemming Society of Interventional Radiology critique and commentary on the Cochrane report on transarterial chemoembolization Hepatology 57 2013 1675 1676
23. A. Bouvier, V. Ozenne, C. Aube, J. Boursier, M.P. Vullierme, and F. Thouveny Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival Eur Radiol 21 2011 1719 1726
24. M. Varela, M.I. Real, M. Burrel, A. Forner, M. Sala, and M. Brunet Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics J Hepatol 46 2007 474 481
25. A. Nicolini, L. Martinetti, S. Crespi, M. Maggioni, and A. Sangiovanni Transarterial chemoembolization with epirubicin-eluting beads vs. transarterial embolization before liver transplantation for hepatocellular carcinoma J Vasc Interv Radiol 21 2010 327 332
26. J. Lammer, K. Malagari, T. Vogl, F. Pilleul, A. Denys, and A. Watkinson Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study Cardiovasc Intervent Radiol 33 2010 41 52
27. R. Golfieri, E. Giampalma, M. Renzulli, R. Cioni, I. Bargellini, and C. Bartolozzi Randomised controlled trial of doxorubicin-eluting beads vs. conventional chemoembolisation for hepatocellular carcinoma Br J Cancer 111 2014 255 264
28. J.M. Llovet, J. Bustamante, A. Castells, R. Vilana, C. Ayuso Mdel, and M. Sala Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials Hepatology 29 1999 62 67
29. J. Bruix, M. Sala, and J.M. Llovet Chemoembolization for hepatocellular carcinoma Gastroenterology 127 2004 S179 S188
30. Italian Association for the Study of the Liver AISF Expert Panel AISF Coordinating Committee L. Bolondi, U. Cillo, and M. Colombo Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma Dig Liver Dis 45 2013 712 723
31. M. Pinter, F. Hucke, I. Graziadei, W. Vogel, A. Maieron, and R. Konigsberg Advanced-stage hepatocellular carcinoma: transarterial chemoembolization vs. sorafenib Radiology 263 2012 590 599
32. J.-W. Park, M. Sherman, M. Colombo, L.R. Roberts, M.E. Schwartz, and F. Degos Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC bridge study: First characterization of the full study population J Clin Oncol 30 Suppl.; abstr. 4033 2012
33. Sherman M, Colombo M, Roberts L, Schwartz M, Degos F, Chen P-J, et al. Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC bridge study: First characterization of the full study population. In: Book of abstracts - ILCA annual conference 2012;abstr. #0-011.
34. L. Bolondi, A. Burroughs, J.F. Dufour, P.R. Galle, V. Mazzaferro, and F. Piscaglia Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions Semin Liver Dis 32 2012 348 359
35. J.L. Raoul, B. Sangro, A. Forner, V. Mazzaferro, F. Piscaglia, and L. Bolondi Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization Cancer Treat Rev 37 2011 212 220
36. M. Burrel, M. Reig, A. Forner, M. Barrufet, C.R. de Lope, and S. Tremosini Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design J Hepatol 56 2012 1330 1335
37. K. Malagari, M. Pomoni, H. Moschouris, E. Bouma, J. Koskinas, and A. Stefaniotou Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis Cardiovasc Intervent Radiol 35 2012 1119 1128
38. K. Takayasu, S. Arii, M. Kudo, T. Ichida, O. Matsui, and N. Izumi Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines J Hepatol 56 2012 886 892
39. V. Mazzaferro, J.M. Llovet, R. Miceli, S. Bhoori, M. Schiavo, and L. Mariani Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis Lancet Oncol 10 2009 35 43
40. F.Y. Yao, L. Xiao, N.M. Bass, R. Kerlan, N.L. Ascher, and J.P. Roberts Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging Am J Transpl 7 2007 2587 2596
41. J.H. Zhong, Y. Ke, W.F. Gong, B.D. Xiang, L. Ma, and X.P. Ye Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma Ann Surg 260 2014 329 340
42. J. Bruix, J.L. Raoul, M. Sherman, V. Mazzaferro, L. Bolondi, and A. Craxi Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial J Hepatol 57 2012 821 829
43. S.R. Alberts, D.J. Sargent, S. Nair, M.R. Mahoney, M. Mooney, and S.N. Thibodeau Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon Cancer: a randomized trial JAMA 307 2012 1383 1393
44. A. Forner, M. Gilabert, J. Bruix, and J.L. Raoul Treatment of intermediate-stage hepatocellular carcinoma Nat Rev Clin Oncol 11 2014 525 535
45. Y. Ha, J.H. Shim, S.O. Kim, K.M. Kim, Y.S. Lim, and H.C. Lee Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis J Gastroenterol Hepatol 29 2014 787 793
46. F. Hucke, M. Pinter, I. Graziadei, W. Vogel, M. Trauner, and W. Sieghart Validation of the BCLC-B subclassification in an Austrian TACE cohort J Hepatol 60 2014 53
47. L. Kadalayil, R. Benini, L. Pallan, J. O'Beirne, L. Marelli, and D. Yu A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular Cancer Ann Oncol 24 2013 2565 2570
48. F. Hucke, M. Pinter, I. Graziadei, S. Bota, W. Vogel, and C. Muller How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma J Hepatol 2014
49. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting results of cancer treatment Cancer 47 1981 207 214
50. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
51. A. Forner, C. Ayuso, M. Varela, J. Rimola, A.J. Hessheimer, and C.R. de Lope Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115 2009 616 623
52. J. Bruix, M. Sherman, J.M. Llovet, M. Beaugrand, R. Lencioni, and A.K. Burroughs Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 2001 421 430
53. J. Bruix, and M. Sherman Practice Guidelines Committee AAftSoLD, Management of hepatocellular carcinoma Hepatology 42 2005 1208 1236
54. J. Bogaerts, R. Ford, D. Sargent, L.H. Schwartz, L. Rubinstein, and D. Lacombe Individual patient data analysis to assess modifications to the RECIST criteria Eur J Cancer 45 2009 248 260
55. R. Lencioni, and J.M. Llovet Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver Dis 30 2010 52 60
56. J.M. Llovet, A.M. Di Bisceglie, J. Bruix, B.S. Kramer, R. Lencioni, and A.X. Zhu Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711
57. R. Gillmore, S. Stuart, A. Kirkwood, A. Hameeduddin, N. Woodward, and A.K. Burroughs EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization J Hepatol 55 2011 1309 1316
58. E.S. Jung, J.H. Kim, E.L. Yoon, H.J. Lee, S.J. Lee, and S.J. Suh Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization J Hepatol 58 2013 1181 1187
59. H.J. Prajapati, J.R. Spivey, S.I. Hanish, B.F. El-Rayes, J.S. Kauh, and Z. Chen MRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE) Ann Oncol 24 2013 965 973
60. J.H. Shim, H.C. Lee, S.O. Kim, Y.M. Shin, K.M. Kim, and Y.S. Lim Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models Radiology 262 2012 708 718
61. J.H. Shim, H.C. Lee, H.J. Won, Y.M. Shin, K.M. Kim, and Y.S. Lim Maximum number of target lesions required to measure responses to transarterial chemoembolization using the enhancement criteria in patients with intrahepatic hepatocellular carcinoma J Hepatol 56 2012 406 411
62. B.K. Kim, S.U. Kim, M.J. Kim, K.A. Kim, Y. Kim do, and J.Y. Park Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization Clin Cancer Res 19 2013 1503 1511
63. R. Lencioni New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma Clin Cancer Res 19 2013 1312 1314
64. A. Riaz, F.H. Miller, L.M. Kulik, P. Nikolaidis, V. Yaghmai, and R.J. Lewandowski Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma JAMA 303 2010 1062 1069
65. C. Georgiades, J.F. Geschwind, N. Harrison, A. Hines-Peralta, E. Liapi, and K. Hong Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment? Radiology 265 2012 115 123
66. J. Choi, J.H. Shim, Y.M. Shin, K.M. Kim, Y.S. Lim, and H.C. Lee Clinical significance of the best response during repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma J Hepatol 60 2014 1212 1218
67. A. Giobbie-Hurder, R.D. Gelber, and M.M. Regan Challenges of guarantee-time bias J Clin Oncol 31 2013 2963 2969
68. R. Golfieri, M. Renzulli, C. Mosconi, L. Forlani, E. Giampalma, and F. Piscaglia Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension? J Vasc Interv Radiol 24 2013 509 517
69. E. Terzi, R. Golfieri, F. Piscaglia, M. Galassi, A. Dazzi, and S. Leoni Response rate and clinical outcome of HCC after first and repeated cTACE performed "on demand" J Hepatol 57 2012 1258 1267
70. I. Bargellini, E. Bozzi, D. Campani, P. Carrai, P. De Simone, and L. Pollina Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants Eur J Radiol 82 2013 e212 e218
71. R. Golfieri, A. Cappelli, A. Cucchetti, F. Piscaglia, M. Carpenzano, and E. Peri Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas Hepatology 53 2011 1580 1589
72. H.Y. Kim, J.W. Park, J. Joo, S.J. Jung, S. An, and S.M. Woo Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma J Gastroenterol Hepatol 27 2012 1051 1056
73. A.L. Cheng, D. Amarapurkar, Y. Chao, P.J. Chen, J.F. Geschwind, and K.L. Goh Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: consensus recommendations and review by an International Expert Panel Liver Int 34 2014 174 183
74. J. Bruix, M. Reig, J. Rimola, A. Forner, M. Burrel, and R. Vilana Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques Hepatology 54 2011 2238 2244
75. R. Lencioni, J.M. Llovet, G. Han, W.-Y. Tak, J. Yang, and M.-A. Leberre Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind SPACE trial J Clin Oncol 30 Suppl. 4; abstr. LBA154 2012
76. W. Sieghart, F. Hucke, M. Pinter, I. Graziadei, W. Vogel, and C. Muller The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma Hepatology 57 2013 2261 2273
77. F. Hucke, W. Sieghart, M. Pinter, I. Graziadei, W. Vogel, and C. Muller The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE J Hepatol 60 2014 118 126
78. A. Xavier, G. Guillaume Penaranda, P. Castellani, H. Perrier, B.L. Pol, and O. Monnet Hepatocellular carcinoma: ART score can predict response after TACE: validation in a large HCC cohort mostly associated with HCV and HBV Hepatology 58 S1 2013 1229A abstr. 2110
79. M. Kudo, G. Han, R.S. Finn, R.T. Poon, J.F. Blanc, and L. Yan Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial Hepatology 60 2014 1697 1707